Compare BZH & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | SANA |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 717.3M | 1.4B |
| IPO Year | 1994 | 2021 |
| Metric | BZH | SANA |
|---|---|---|
| Price | $22.54 | $5.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $32.00 | $7.83 |
| AVG Volume (30 Days) | 504.8K | ★ 5.1M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $2,371,555,000.00 | N/A |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $17.37 | $1.26 |
| 52 Week High | $32.21 | $7.30 |
| Indicator | BZH | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 61.08 |
| Support Level | $21.50 | $4.25 |
| Resistance Level | $23.21 | $5.43 |
| Average True Range (ATR) | 0.80 | 0.50 |
| MACD | 0.09 | 0.14 |
| Stochastic Oscillator | 60.56 | 84.27 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in over 13 states and over 22 metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the leading sources of revenue for the company. Key metro areas include Atlanta, Las Vegas, Los Angeles, Orlando, and Tampa. The company also focuses on land purchasing and development to support future construction efforts as well as mortgage services for its homebuyers.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.